Undisclosed IPF therapeutic / Surrozen - LARVOL DELTA

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis (GlobeNewswire) - "Surrozen, Inc...announced a strategic research collaboration with privately-held TCGFB, Inc. ('TCGFB') to discover antibody therapeutics targeting Transforming Growth Factor Beta (TGF-β) for the potential treatment of patients with idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-β product related intellectual property."

Licensing / partnership • Idiopathic Pulmonary Fibrosis